多激酶抑制剂联合PD-1抑制剂在肝胆管结石合并胆管癌患者中的疗效与安全性研究  

Study on the Efficacy and Safety of Multi-Kinase Inhibitor Combined with PD-1 Inhibitor in Patients with Hepatobiliary Stones Combined with Cholangiocarcinoma

作　　者：王庆元[1] 冯明明[1] 李涛 WANG Qingyuan;FENG Mingming;LI Tao(Nanyang Central Hospital,General Surgery Hepatobiliary Disease Department,Nanyang Henan 473000,China)

机构地区：[1]南阳市中心医院普通外科胆道病区,河南南阳473000

出　　处：《临床研究》2025年第1期83-86,共4页Clinical Research

摘　　要：目的探讨酪氨酸激酶抑制剂(TKI)联合程序性死亡蛋白-1(PD-1)抑制剂在肝胆管结石合并胆管癌患者中的疗效与安全性。方法研究选取了2021年2月至2024年2月期间在南阳市中心医院接受治疗的81例肝胆管结石合并胆管癌患者,根据治疗方式分为观察组(TKI联合PD-1抑制剂治疗)39例和对照组(TKI单独治疗)42例。比较两组患者的一般资料(性别、年龄、病程、主要症状、肝功能分级、肿瘤分期及TKI使用情况)、疗效评估,以及不良反应发生情况,结果两组患者一般资料(性别比例、年龄、病程、主要症状、肝功能分级、肿瘤分期及TKI使用情况)比较,差异无统计学意义(P>0.05)。观察组患者的疾病控制率明显高于对照组,差异具有统计学意义(P<0.05),但两组客观缓解率比较,差异无统计学意义(P>0.05)。两组患者的不良反应(肝功能异常、皮疹、血小板减少、恶心呕吐、免疫性肝损伤、中性粒细胞减少、白细胞减少)发生情况比较,差异无统计学意义(P>0.05)。结论TKI联合PD-1抑制剂在治疗肝胆管结石合并胆管癌患者中具有一定疗效,疾病控制率较优,且安全性较好,不会额外增加不良反应。Objective To explore the efficacy and safety of Tyrosine Kinase Inhibitor(TKI)combined with Programmed Death Protein-1(PD-1)inhibitor in patients with hepatobiliary stones combined with cholangiocarcinoma.Methods study included 81 patients with hepatobiliary stones combined with cholangiocarcinoma who were treated at Nanyang Central Hospital from February 2021 to February 2024.Patients were divided into the observation group(39 patients receiving TKI combined with PD-1 inhibitor treatment)and the control group(42 patients receiving TKI treatment alone)based on the treatment method.The general characteristics of the two groups(gender,age,course of disease,main symptoms,liver function grade,tumor stage,and TKI usage),efficacy assessment,and the occurrence of adverse reactions were compared.Results There were no statistically significant differences in the general characteristics of the two groups(gender ratio,age,course of disease,main symptoms,liver function grade,tumor stage,and TKI usage)(P>0.05).The disease control rate in the observation group was significantly higher than that in the control group,with a statistically significant difference(P<0.05),but there was no statistically significant difference in the objective response rate between the two groups(P>0.05).The occurrence of adverse reactions(abnormal liver function,rash,thrombocytopenia,nausea and vomiting,immune-related liver injury,neutropenia,and leukopenia)was compared between the two groups,and no statistically significant difference was found(P>0.05).Conclusion TKI combined with PD-1 inhibitor has a certain efficacy in treating patients with hepatobiliary stones combined with cholangiocarcinoma,with a superior disease control rate and good safety,without significantly increasing adverse reactions.

关 键 词：多激酶抑制剂 程序性死亡蛋白-1抑制剂 肝胆管结石 胆管癌 安全性 

分 类 号：R735.8[医药卫生—肿瘤]